Swart, Joost
,
Giancane, Gabriella
Horneff, Gerd
Magnusson, Bo
Hofer, Michael
Alexeeva, Еkaterina
Panaviene, Violeta
Bader-Meunier, Brigitte
Anton, Jordi
Nielsen, Susan
De Benedetti, Fabrizio
Kamphuis, Sylvia
Staņēviča, Valda
Tracahana, Maria
Ailioaie, Laura Marinela
Tsitsami, Elena
Klein, Ariane
Minden, Kirsten
Foeldvari, Ivan
Haas, Johannes Peter
Klotsche, Jens
Horne, Anna Carin
Consolaro, Alessandro
Bovis, Francesca
Bagnasco, Francesca
Pistorio, Angela
Martini, Alberto
Wulffraat, Nico
Ruperto, Nicolino http://orcid.org/0000-0001-8407-7782
Funding for this research was provided by:
FP7 Health (260353)
IRCCS Istituto Giannina Gaslini (Internal research funds)
Article History
Received: 21 May 2018
Accepted: 27 November 2018
First Online: 27 December 2018
Ethics approval and consent to participate
: All registries and participating centers obtained approval from their respective ethics committees and were conducted in accordance with the Declaration of Helsinki. All subjects provided written informed consent/assent based on existing national regulations.
: Not applicable.
: JS has received a research a grant from Pfizer. GH has received research funds from, has acted as a consultant for, and has participated in speaker bureaus for AbbVie, Chugai, Novartis, Pfizer Inc., and Roche. BM has acted as a principal investigator for Novartis and Enzyvant. MH has received a grant from AbbVie and a grant and personal fees from Novartis. EA has received research grants from Roche, Abbott, Pfizer, Bristol-Myers Squibb, Centocor, and Novartis and has received honoraria as a speaker for Roche, Novartis, and Pfizer. BB-M has participated as co-investigator to clinical trials from Pfizer, Abbott, Novartis, and Roche. JA has received grants and personal fees (consulting lecturers and speakers’ bureau) and has been member of advisory groups for Pfizer, AbbVie, Roche, Sobi, Novartis, and Gebro. FDB receives consultancy/unrestricted research grants from AbbVie, Gilead, Novartis, Novimmune, Pfizer, Roche, Sanofi, Sobi, and UCB. VS has research collaborations with Pfizer and has received consulting fees from AbbVie and Roche. KM is funded by the German Rheumastiftung and has received research grants from Pfizer, AbbVie, and Roche and honoraria from AbbVie, Genzyme, Medac, and Pharm-Allergan. IF has received personal fees from AbbVie, Chugai, and Novartis and has acted as a consultant for Genentech, Bayer, Medac, and Lilly. AM does not have any conflict of interest to declare since March 2016, when he became the Scientific Director of the public hospital IRCCS Istituto Giannina Gaslini because this role does not allow him to render private consultancy resulting in personal income. He performed consultancy activities on behalf of the public hospital IRCCS Istituto Giannina Gaslini for AbbVie, Boehringer, Novartis, and R-Pharm and is the Scientific Director of the public hospital IRCCS Istituto Giannina Gaslini, which has received funds from Bristol-Myers Squibb, Hoffman-La Roche, Janssen, Novartis, Pfizer Inc., and Sobi for the coordination activity of the PRINTO network. NW has received research grants from Pfizer and AbbVie and personal fees from Novartis. NR has acted as a consultant and has participated in speaker bureaus for AbbVie, Ablynx, Amgen, AstraZeneca, Baxalta Biosimilars, Biogen Idec, Boehringer, Bristol-Myers Squibb, Celgene, Eli-Lilly, EMD Serono, Gilead Sciences, Janssen, Medimmune, Novartis, Pfizer Inc., R-Pharm, Roche, Sanofi, Servier, and Takeda and works as a full-time public employee of the public hospital IRCCS Istituto Giannina Gaslini, which has received funds from Bristol-Myers Squibb, Hoffman-La Roche, Janssen, Novartis, Pfizer Inc., and Sobi for the coordination activity of the PRINTO network. The other authors declare that they have no competing interests.
: Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.